HMGB2 and hepatocellular carcinoma: Then, using an orthotopic HCC model in immunocompetent mice, we demonstrated that Hmgb2 knockdown in tumor cells combined with PD-1 antibody effectively reduced tumor burden (Fig. 6, F and G) and extended survival time (Fig. 6H).